PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Previous research has shown a 40% decrease in hepatic PGC-1α expression in NAFLD patients, accompanied by mitochondrial dysfunction, lipid accumulation, and insulin resistance [17].